14:14 , Mar 25, 2019 |  BioCentury  |  Emerging Company Profile

China Oncology Focus: funding combinations

China Oncology Focus aims to differentiate itself from other Chinese in-licensing plays by leveraging the diversity of its pipeline to develop in-house combination therapies, with its PD-L1 therapy as a backbone. The company is seeking...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
18:05 , May 25, 2018 |  BioCentury  |  Finance

HKEX’s on-demand experts

The Hong Kong stock exchange is well aware its investor base is new to the high-risk, high-reward nature of its newly hatched biotech chapter and has no qualms about admitting its own lack of expertise....
22:19 , Mar 16, 2018 |  BioCentury  |  Finance

Hong Kong’s new chapter

Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks. It promises to create a long sought public capital market for...
22:47 , Jan 5, 2018 |  BC Week In Review  |  Company News

Angiochem grants Xinogen Chinese rights to ANG1005

Angiochem Inc. (Montreal, Quebec) granted Xinogen Hong Kong Pharma Co. Ltd. exclusive, Chinese rights to develop and commercialize ANG1005 to treat leptomeningeal carcinomatosis and brain metastases arising from metastatic breast cancer. The therapy is a...
12:08 , Jan 3, 2018 |  BC Extra  |  Company News

Angiochem, Xinogen in China deal

Angiochem Inc. (Montreal, Quebec) granted an exclusive license in China to Xinogen Hong Kong Pharma Co. Ltd. to develop and commercialize ANG1005 to treat leptomeningeal carcinomatosis and brain metastases arising from metastatic breast cancer. The...
00:14 , Dec 14, 2017 |  BC Extra  |  Company News

BayHelix names new board

BayHelix Group elected Victor Shi, Jun Bao, Wendy Pan, Debra Yu, Zoey Wang, Carol Zhu and James Li to serve as its board of directors in 2018-19. The board will elect and announce a chairperson...
00:03 , Dec 1, 2017 |  BC Week In Review  |  Company News

Shenogen, Lee's forge another cancer combo deal

Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) and Shenogen Pharma Group Ltd. (Beijing, China) partnered to jointly develop and commercialize a combination therapy in China to treat late-stage cancers. The therapy will comprise Lee's ZKAB001, which is...
22:01 , Nov 20, 2017 |  BC Extra  |  Company News

Shenogen, Lee's forge another cancer combo deal

Lee's Pharmaceutical Holdings Ltd. (HKSE:0950) and Shenogen Pharma Group Ltd. (Beijing, China) partnered to jointly develop and commercialize a combination therapy in China to treat late-stage cancers. The therapy will comprise ZKAB001, which is a...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Lee’s Pharmaceutical Holdings Ltd., Shenogen Pharma deal

Lee’s Pharmaceutical and Shenogen partnered to develop and commercialize Lee’s Pharmaceutical’s Pexa-Vec in combination with Shenogen’s icaritin in China to treat late-stage cancers. The partners said a Phase II trial of icaritin to treat hepatocellular...